Since there was no equal distribution of patients between the groups, the data were analyzed as follows: among the women who received carbetocin, only four (5.5%) experienced postpartum hemorrhage, whereas among the women who received oxytocin, 16 (22.2%) experienced postpartum hemorrhage, a difference that was statistically significant. This evidence concerns the gene OXT and postpartum hemorrhage.